1. Market Research
  2. > Endotis Pharma - Product Pipeline Review - 2013

Endotis Pharma - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

Endotis Pharma - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Endotis Pharma - Product Pipeline Review - 2013” provides data on the Endotis Pharma’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Endotis Pharma’s corporate website, SEC filings, investor presentations and featured press releases, both from Endotis Pharma and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Endotis Pharma - Brief Endotis Pharma overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Endotis Pharma human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Endotis Pharma with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Endotis Pharma’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Endotis Pharma’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Endotis Pharma in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Endotis Pharma’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Endotis Pharma.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Endotis Pharma and identify potential opportunities in those areas.

Table Of Contents

Endotis Pharma - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Endotis Pharma Snapshot 4
Endotis Pharma Overview 4
Key Information 4
Key Facts 4
Endotis Pharma - Research and Development Overview 5
Key Therapeutic Areas 5
Endotis Pharma - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Endotis Pharma - Pipeline Products Glance 9
Endotis Pharma Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Endotis Pharma - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Endotis Pharma - Drug Profiles 12
EP-217609 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
EP-37 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
EP-5001 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
EP-80061 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
fondaparinux sodium 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Endotis Pharma - Pipeline Analysis 18
Endotis Pharma - Pipeline Products by Therapeutic Class 18
Endotis Pharma - Pipeline Products by Route of Administration 19
Endotis Pharma - Pipeline Products By Mechanism of Action 20
Endotis Pharma - Recent Pipeline Updates 21
Endotis Pharma - Dormant Projects 22
Endotis Pharma - Locations And Subsidiaries 23
Head Office 23
Other Locations and Subsidiaries 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables


Endotis Pharma, Key Information 4
Endotis Pharma, Key Facts 4
Endotis Pharma - Pipeline by Indication, 2013 6
Endotis Pharma - Pipeline by Stage of Development, 2013 7
Endotis Pharma - Monotherapy Products in Pipeline, 2013 8
Endotis Pharma - Phase II, 2013 9
Endotis Pharma - Phase I, 2013 10
Endotis Pharma - Pre-Clinical, 2013 11
Endotis Pharma - Pipeline By Therapeutic Class, 2013 18
Endotis Pharma - Pipeline By Route of Administration, 2013 19
Endotis Pharma - Pipeline Products By Mechanism of Action, 2013 20
Endotis Pharma - Recent Pipeline Updates, 2013 21
Endotis Pharma - Dormant Developmental Projects,2013 22
Endotis Pharma, Other Locations 23

List of Figures


Endotis Pharma - Pipeline by Indication, 2013 6
Endotis Pharma - Pipeline by Stage of Development, 2013 7
Endotis Pharma - Monotherapy Products in Pipeline, 2013 8
Endotis Pharma - Pipeline By Therapeutic Class, 2013 18
Endotis Pharma - Pipeline By Route of Administration, 2013 19
Endotis Pharma - Pipeline Products By Mechanism of Action, 2013 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.